



## Curriculum Vitae

Personal information **Pieter Van de Vijver**

### Work experience

---

1. Start date 23.02.2026 - current

**IMPD apotheker**  
**Klinische Farmacie en Toxicologie, Maastricht University Medical Center+**  
**The Netherlands**

(pre)-assessor involved in the assessment of clinical trial applications for the Maastricht University Medical Center+ Medical Ethics Review Board

2. Start date: 19.08.2024

End date: 22.02.2026

**Non-clinical Assessor (Human Medicines)**  
**Federal Agency for Medicines and Health Products**  
**Belgium**

Scientific expert, mainly involved in the assessment of non-clinical aspects of applications for clinical trials with medicinal products. Additional tasks include non-clinical aspects of national procedures, non-clinical assessment of centralized procedures and providing scientific-regulatory advice. Additional expertise areas: radiopharmaceuticals, small molecule antivirals, toxicology of impurities and leachables, dermatological products, particulate toxicity. I also act as a support expert to the ICH Q3E expert working group, on behalf of EMA/EC.

3. Start date: 01.03.2014

End date: 18.08.2024

**Non-clinical Assessor (Medical Devices)**  
**Federal Agency for Medicines and Health Products**  
**Belgium**

Scientific assessor, mainly involved in the non-clinical/safety assessment of clinical trial applications (medicinal products) and clinical investigation applications (medical devices). Additional tasks and responsibilities: involvement in Scientific Advice Procedures; parallel review of technical files (medical devices); providing expertise on number of subjects: biological safety (biocompatibility) of medical devices, non-clinical aspects of medical devices and medicinal products, toxicological aspects of medical devices, drug-device combination products.

4. Start date: 01.11.2013

End date: 28.02.2014

**Scientific Account Manager**  
**Federal Agency for Medicines and Health Products**  
**Belgium**

Main tasks: support of the STA unit at FAMHP, providing scientific and regulatory advice related to the development of human medicinal products and medical devices (prior to clinical trials or market authorization applications).

5 Start date: 30.09.2008

End date: 30.10.2013

**Postdoctoral Researcher**  
**Cardiovascular Research Institute Maastricht, Department of Biochemistry, Maastricht University**  
**The Netherlands**

Main activities: scientific research in the fields of peptide synthesis, chemical protein synthesis, development of diagnostics, bioconjugation. Teaching and coaching.

6. Start date: 01.09.2003

End date: 30.09.2008

**PhD Student**  
**Employer: Rega Institute for Medical Research (Katholieke Universiteit Leuven)**  
**Belgium**

Main activities: scientific research (medicinal chemistry) and teaching.

### Education and training

---

1. Start date: 01.09.2003

End date: 16.09.2008

**PhD in Pharmaceutical Sciences**  
Institution: Faculty of Pharmaceutical Sciences (Katholieke Universiteit Leuven)  
Belgium

Subjects: medicinal chemistry; design, synthesis and testing of antibacterial and immunosuppressive agents.  
Teaching.

2. Start date: 01.09.1998

End date: 05.07.2003

**Apotheker (Master in Pharmaceutical Sciences)**  
Institution: Faculty of Pharmaceutical Sciences (Katholieke Universiteit Leuven)  
Belgium

## Additional information

---

### Publications

Annemiek Dickhout, **Pieter van de Vijver**, Nicole Bitsch, Stefan J van Hoof, M. Christella L. G. D. Thomassen, Steffen Massberg, Peter Timmerman, Frank Verhaegen, Rory R. Koenen, Ingrid Dijkgraaf, Tilman M. Hackeng, Molecular detection of venous thrombosis in murine models using SPECT/CT, 2022, *Biomolecules*, 12, 829

Stijn M Agten, Dennis Suylen, Hans Ippel, Maria Kokozidou, Guido Tans, **Pieter Van de Vijver**, Rory R Koenen, Tilman M Hackeng. Chemoselective oxime reactions in proteins and peptides by using an optimized oxime strategy: the demise of levulinic acid, *ChemBioChem* 2013, 14(18), 2431-4

Ingrid Dijkgraaf, **Pieter Van de Vijver**, Anouk Dirksen, Tilman M. Hackeng. Synthesis and application of cNGR-containing imaging agents for detection of angiogenesis. *Bioorganic & Medicinal Chemistry* 2013, 21(12), 3555-64

**Pieter Van de Vijver**, Martin Schmitt, Dennis Suylen, Liesbeth Scheer, M. Christella L.G.D. Thomassen, Leon Schurgers, John Griffin, Rory Koenen, Tilman M. Hackeng. Incorporation of Disulfide Containing Protein Modules into Multivalent Antigenic Conjugates - Generation of Antibodies against the Thrombin-Sensitive Region of Murine Protein S. *Journal of the American Chemical Society* 2012, 134(47), 19318-21

**Pieter Van de Vijver**, Liesbeth Scheer, Judy van Beijnum, Arjan Griffioen, Tilman M. Hackeng. Application of an omonasteine ligation strategy for the total chemical synthesis of the BRD7 bromodomain. *Chemical Communications* 2012, 48(75), 9403-5

**Pieter Van de Vijver**, Dennis Suylen, Anouk Dirksen, Philip Dawson, Tilman M. Hackeng. Nε-(Thiopropyl)-lysine as a Handle for Site-Specific Protein Conjugation *Biopolymers* 2010, 94(4), 465-474

**Pieter Van de Vijver**, Gaston Vondenhoff, Teymur Kazakov, Ekaterina Semanova, Konstantin Kuznedelov, Anastasia Metlitskaya, Arthur Van Aerschot, Konstantin Severinov. Synthetic Microcin C Analogs Targeting Different Aminoacyl-tRNA Synthetases *Journal of Bacteriology* 2009, 191(20), 6273-6280

**Pieter Van de Vijver**, Gaston Vondenhoff, Samgar Denivelle, Jef Rozenski, Jan Verhaegen, Arthur Van Aerschot, and Piet Herdewijn. Antibacterial 5'-O-(N-dipeptidyl)-sulfamoyladenines *Bioorganic & Medicinal Chemistry* 2009, 17(1), 260-269

**Pieter Van de Vijver**, Tomasz Ostrowski, Brian Sproat, Jozef Goebels, Omer Rutgeerts, Arthur Van Aerschot, Mark Waer, and Piet Herdewijn. Aminoacyl-tRNA synthetase inhibitors as potent and synergistic immunosuppressants. *Journal of Medicinal Chemistry* 2008, 51(10), 3020- 3029

### Projects

### Memberships

*BelTox* - The Belgian Society of Toxicology and Ecotoxicology

### Other Relevant Information

European Registered Toxicologist (ERT)